AAAAAA

   
Results: 1-10 |
Results: 10
Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology
Authors: Schiffer, CA Anderson, KC Bennett, CL Bernstein, S Elting, LS Goldsmith, M Goldstein, M Hume, H McCullough, JJ McIntyre, RE Powell, BL Rainey, JM Rowley, SD Rebulla, P Troner, MB Wagnon, AH
Citation: Ca. Schiffer et al., Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology, J CL ONCOL, 19(5), 2001, pp. 1519-1538
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia
Authors: Elting, LS Rubenstein, EB Martin, CG Kurtin, D Rodriguez, S Laiho, E Kanesan, K Cantor, SB Benjamin, RS
Citation: Ls. Elting et al., Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia, J CL ONCOL, 19(4), 2001, pp. 1137-1146
Severity of illness, outcomes, and resource use in elderly cancer patientswith deep venous thrombosis
Authors: Escalante, CP Kurtin, D Rivera, E Elting, LS
Citation: Cp. Escalante et al., Severity of illness, outcomes, and resource use in elderly cancer patientswith deep venous thrombosis, CL APPL T-H, 6(3), 2000, pp. 175-178
Identifying risk factors for imminent death in cancer patients with acute dyspnea
Authors: Escalante, CP Martin, CG Elting, LS Price, KJ Manzullo, EF Weiser, MA Harle, TS Cantor, SB Rubenstein, EB
Citation: Cp. Escalante et al., Identifying risk factors for imminent death in cancer patients with acute dyspnea, J PAIN SYMP, 20(5), 2000, pp. 318-325
Time to clinical response: An outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care
Authors: Elting, LS Rubenstein, EB Rolston, K Cantor, SB Martin, CG Kurtin, D Rodriguez, S Lam, T Kanesan, K Bodey, G
Citation: Ls. Elting et al., Time to clinical response: An outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care, J CL ONCOL, 18(21), 2000, pp. 3699-3706
Influence of data display formats on decisions to stop clinical trials - Reply
Authors: Elting, LS Martin, CG Rubenstein, EB
Citation: Ls. Elting et al., Influence of data display formats on decisions to stop clinical trials - Reply, BR MED J, 319(7216), 1999, pp. 1070-1070
Influence of data display formats on physician investigators' decisions tostop clinical trials: prospective trial with repeated measures
Authors: Elting, LS Martin, CG Cantor, SB Rubenstein, EB
Citation: Ls. Elting et al., Influence of data display formats on physician investigators' decisions tostop clinical trials: prospective trial with repeated measures, BR MED J, 318(7197), 1999, pp. 1527-1531
Integrating prophylactic measures into practice guidelines for platelet growth factors - Selection of patients
Authors: Elting, LS
Citation: Ls. Elting, Integrating prophylactic measures into practice guidelines for platelet growth factors - Selection of patients, ONCOLOGY-NY, 13(11A), 1999, pp. 587-589
Outpatient management of neutropenic fever: Antibiotics, growth factors orboth?
Authors: Rubenstein, EB Elting, LS Sun, CC Rolston, KVI
Citation: Eb. Rubenstein et al., Outpatient management of neutropenic fever: Antibiotics, growth factors orboth?, CLINICAL APPLICATIONS OF CYTOKINES AND GROWTH FACTORS, 1999, pp. 159-177
Mississippi mud in the 1990s - Risks and outcomes of vancomycin-associatedtoxicity in general oncology practice
Authors: Elting, LS Rubenstein, EB Kurtin, D Rolston, KVI Fangtang, J Martin, CG Raad, II Whimbey, EE Manzullo, E Bodey, GP
Citation: Ls. Elting et al., Mississippi mud in the 1990s - Risks and outcomes of vancomycin-associatedtoxicity in general oncology practice, CANCER, 83(12), 1998, pp. 2597-2607
Risultati: 1-10 |